Ginkgo snares $18M contract from US government to research complex protein production

Preview

来源: FiercePharma

Ginkgo Bioworks signed on to work with the Defense Advanced Research Projects Agency to research the manufacturing of complex therapeutic proteins.

Ginkgo Bioworks, which has developed a platform for cell programming and biosecurity, has entered a contract valued at up to $18 million with the U.S. Defense Advanced Research Projects Agency (DARPA). Under the deal, the company will research the manufacturing of complex therapeutic proteins.

As part of the federal agency’s Reimagining Protein Manufacturing project, Ginkgo aims to leverage its cell-free protein synthesis technology to advance fast, high-yield production of human therapeutic proteins, the company said in a July 19 press release.

The overarching goal of the work is help shore up supply chains in the future and have the ability to meet immediate therapeutic needs in specific geographic regions, GinkgoGinkgo added.

“There is growing recognition that pharmaceutical supply chains are at risk,” Jason Kelly, co-founder and chief executive of Ginkgo, said in the release. “One way to meet this challenge is distributed manufacturing at the point of care. Imagine a future where drugs, including complex biologics, are produced locally or in a widely distributed manner on-demand.”

Therapeutic proteins with “post-translational modifications” such as antibodies, cytokines and clotting factors are important both to the biopharma marketplace and to DARPA. Currently, about half of the top-selling drugs used to treat cancer and autoimmune diseases contain such therapeutic proteins.

Those same drugs are also used to treat or prevent disease, injury or death related to chemical, biological, radiological or nuclear threats.

Also working on the team with Ginkgo are researchers from Imperial College London including Paul Freemont of Nature’s Toolbox, Alex Koglin and consultant Michael Feldhaus, who is a former executive vice president of antibody discovery at Adimab.

In early June, Ginkgo announced a collaboration with Novo Nordisk to create novel expression hosts for pharmaceutical products. Financial terms of that collaboration weren’t disclosed.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。